<DOC>
	<DOC>NCT00716092</DOC>
	<brief_summary>The objective of this study is to investigate the effect of BI 1356 on 24-h glucose control and various pharmacodynamic parameters in type 2 diabetic patients with inadequate glycaemic control.</brief_summary>
	<brief_title>The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Inclusion criteria: Male and female patients with a diagnosis of type 2 diabetes mellitus and previously treated with not more than one drug Glycosylated haemoglobin A1 (HbA1c) 6.5 to 10.0% at Start of Runin Exclusion criteria: Myocardial infarction, stroke or transient ischemic attack "TIA" within 6 months prior to informed consent Impaired hepatic function Renal insufficiency with a creatinine clearance &lt; 50 mL/min Treatment with rosiglitazone, pioglitazone, glucagon like peptide 1 (GLP1) analogues, insulin, dipeptidyl peptidase 4 (DPP4) inhibitors or antiobesity drugs 3 months prior to informed consent.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>